Alliance Pharma Backs £362m Takeover by DBAY Advisors

The UK-based healthcare firm’s board recommends the revised offer, with shareholders set to vote on the deal this week.

DBAY Advisors, Alliance Pharma's largest shareholder, increased its offer to 64.75p per share, valuing the company at £362 million.
The revised bid represents a 46% premium over Alliance Pharma's share price prior to DBAY’s initial approach in January 2025.
Alliance Pharma’s board and its second-largest shareholder, Slater Investments, which holds a 13.5% stake, have endorsed the deal.
Shareholders will vote on the proposal on March 13, with the acquisition expected to finalize in the first half of 2025 if approved.
The deal would result in Alliance Pharma delisting from London’s AIM market and becoming a privately owned company under DBAY’s control.